SEC Company Response from BeOne Medicines Ltd. (ONC, BEIGF) (CIK 0001651308) (ONC) — Dec 9, 2015
BeOne Medicines Ltd. (ONC, BEIGF) (CIK 0001651308)
Date: Dec. 9, 2015 · CIK: 0001651308 · Accession: 0001104659-15-083853
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-207459
Referenced dates: October 28, 2015
Letter
VIA EDGAR AND FEDERAL EXPRESS Division of Corporation Finance Attention: Suzanne Hayes BeiGene, Ltd. Registration Statement on Form S-1 Filed October 16, 2015 File No. 333-207459
Dear Ms. Hayes:
This letter is being submitted on behalf of BeiGene, Ltd. (the “Company”) in response to the comments of the staff of the Division of Corporation Finance (the “Staff”) of the U.S. Securities and Exchange Commission (the “Commission”) with respect to the Company’s Registration Statement on Form S-1 filed on October 16, 2015 (the “Registration Statement”), as set forth in your letter dated October 28, 2015 addressed to Mr. John V. Oyler, Chief Executive Officer and Chairman of the Company (the “Comment Letter”). The Company is concurrently filing an Amendment No. 1 to the Registration Statement on Form S-1 (the “Amendment No. 1”), which includes changes to reflect responses to the Staff’s comments.
For reference purposes, the text of the Comment Letter has been reproduced herein with responses below each numbered comment. For your convenience, we have italicized the reproduced Staff comments from the Comment Letter. Unless otherwise indicated, page references in the Staff’s comments refer to the Registration Statement, and page references in the responses refer to the Amendment No. 1.
The responses provided herein are based upon information provided to Goodwin Procter LLP by the Company. In addition to submitting this letter via EDGAR, we are sending via Federal Express two copies of each of this letter and the Amendment No. 1 (marked to show changes from the Registration
Statement).
Management’s Discussion and Analysis of Financial Condition and Results of Operations
Results of Operations
Research and Development Expense, page 107
1. We acknowledge your response to comment 11. We believe disclosing the cost of each of your key development programs is helpful to an understanding of your use of resources. If you do not maintain research and development costs by project, disclose that fact and explain why management does not maintain and evaluate research and development costs by project. Provide other quantitative or qualitative disclosure that indicates the amount of the company´s resources being used on the project.
RESPONSE: In response to the Staff’s comment, the Company has revised the disclosures on pages 109 and 111–112.
Business
Collaboration with Merck KGaA, page 171
2. Please revise your disclosure to indicate the approximate ranges of the royalty payments to be paid by you to Merck KGaA under the license agreements.
RESPONSE: In response to the Staff’s comment, the Company has revised the disclosures on pages 104 and 179 to indicate the approximate range of the royalty payments to be paid to the Company by Merck KGaA under the license agreement.
***
If you should have any questions concerning the enclosed matters, please contact the undersigned at (212) 813-8853.
Sincerely,
/s/ Edwin O’Connor
Show Raw Text
CORRESP 1 filename1.htm Edwin O’Connor Goodwin Procter LLP 212-813-8853 Counselors at Law EOConnor@goodwinprocter.com Exchange Place Boston, MA 02109 T: 617.570.1000 F: 617.523.1231 December 9, 2015 VIA EDGAR AND FEDERAL EXPRESS U.S. Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Attention: Suzanne Hayes Re: BeiGene, Ltd. Registration Statement on Form S-1 Filed October 16, 2015 File No. 333-207459 Dear Ms. Hayes: This letter is being submitted on behalf of BeiGene, Ltd. (the “Company”) in response to the comments of the staff of the Division of Corporation Finance (the “Staff”) of the U.S. Securities and Exchange Commission (the “Commission”) with respect to the Company’s Registration Statement on Form S-1 filed on October 16, 2015 (the “Registration Statement”), as set forth in your letter dated October 28, 2015 addressed to Mr. John V. Oyler, Chief Executive Officer and Chairman of the Company (the “Comment Letter”). The Company is concurrently filing an Amendment No. 1 to the Registration Statement on Form S-1 (the “Amendment No. 1”), which includes changes to reflect responses to the Staff’s comments. For reference purposes, the text of the Comment Letter has been reproduced herein with responses below each numbered comment. For your convenience, we have italicized the reproduced Staff comments from the Comment Letter. Unless otherwise indicated, page references in the Staff’s comments refer to the Registration Statement, and page references in the responses refer to the Amendment No. 1. The responses provided herein are based upon information provided to Goodwin Procter LLP by the Company. In addition to submitting this letter via EDGAR, we are sending via Federal Express two copies of each of this letter and the Amendment No. 1 (marked to show changes from the Registration Statement). Management’s Discussion and Analysis of Financial Condition and Results of Operations Results of Operations Research and Development Expense, page 107 1. We acknowledge your response to comment 11. We believe disclosing the cost of each of your key development programs is helpful to an understanding of your use of resources. If you do not maintain research and development costs by project, disclose that fact and explain why management does not maintain and evaluate research and development costs by project. Provide other quantitative or qualitative disclosure that indicates the amount of the company´s resources being used on the project. RESPONSE: In response to the Staff’s comment, the Company has revised the disclosures on pages 109 and 111–112. Business Collaboration with Merck KGaA, page 171 2. Please revise your disclosure to indicate the approximate ranges of the royalty payments to be paid by you to Merck KGaA under the license agreements. RESPONSE: In response to the Staff’s comment, the Company has revised the disclosures on pages 104 and 179 to indicate the approximate range of the royalty payments to be paid to the Company by Merck KGaA under the license agreement. *** 2 If you should have any questions concerning the enclosed matters, please contact the undersigned at (212) 813-8853. Sincerely, /s/ Edwin O’Connor Edwin O’Connor Enclosures cc: John V. Oyler, Chief Executive Officer and Chairman, BeiGene, Ltd. Howard Liang, Chief Financial Officer and Chief Strategy Officer, BeiGene, Ltd. Mitchell S. Bloom, Goodwin Procter LLP Michael J. Kendall, Goodwin Procter LLP Qing Nian, Goodwin Procter LLP Bruce K. Dallas, Davis Polk & Wardwell LLP 3